Investor Relations

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vital Therapies Appoints Former Receptos President and CEO Faheem Hasnain as Chairman of the Board of Directors
SAN DIEGO , Sept. 06, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced the appointment of Faheem Hasnain as Chairman of the Board of Directors,
View HTML
Toggle Summary Vital Therapies Announces Recent and Upcoming Scientific Presentations and Participation in Upcoming Investor Conference
SAN DIEGO , Sept. 11, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today provides an update on recent and upcoming scientific presentations.
View HTML
Toggle Summary Vital Therapies Announces Upcoming Third Quarter Financial Results Conference Call With Webcast
SAN DIEGO , Oct. 18, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its third quarter 2017 financial results after the market closes on Wednesday,
View HTML
Toggle Summary Vital Therapies Announces Third Quarter 2017 Financial Results
- 118 of Targeted 150 Subjects Enrolled in VTL-308 as of October 24th SAN DIEGO , Oct. 25, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced results
View HTML
Toggle Summary Vital Therapies to Webcast Presentation at Upcoming Investor Conference
SAN DIEGO , Nov. 08, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that the company will participate in the Stifel 2017 Healthcare Conference in
View HTML
Toggle Summary Vital Therapies Appoints Russell J. Cox as Chief Executive Officer and Board Member Effective January 3, 2018
EVP and Chief Operating Officer of Jazz Pharmaceuticals brings significant experience commercializing new therapies SAN DIEGO , Dec. 04, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute
View HTML
Toggle Summary Vital Therapies Added to NASDAQ Biotechnology Index
SAN DIEGO , Dec. 11, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced that it has been selected for addition to the NASDAQ Biotechnology Index®, which
View HTML
Toggle Summary Vital Therapies Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SAN DIEGO , Jan. 05, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today reported a grant under its 2017 Inducement Equity Incentive Plan to Russell Cox , who
View HTML
Toggle Summary Vital Therapies Announces Upcoming Fourth Quarter and Full Year Financial Results Conference Call with Webcast and Participation in Upcoming Conference
SAN DIEGO , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, will release its fourth quarter and full year 2017 financial results after the market closes on
View HTML
Toggle Summary Vital Therapies Announces Fourth Quarter and Full Year 2017 Financial Results
- VTL-308 Enrollment Nears Completion with 147 Subjects Enrolled as of March 12 - On Track for Release of Topline Results in Third Quarter of 2018 SAN DIEGO , March 13, 2018 (GLOBE NEWSWIRE) --   Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy
View HTML